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Summary
Background Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell 
lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated 
by autologous haematopoietic stem-cell transplantation (HSCT) in patients with secondary CNS lymphoma.
Methods This international, single-arm, phase 2 trial was done in 24 hospitals in Italy, the UK, the Netherlands, and 
Switzerland. Adults (aged 18–70 years) with histologically diagnosed diffuse large B-cell lymphoma and CNS involvement 
at the time of primary diagnosis or at relapse and Eastern Cooperative Oncology Group Performance Status of 3 or less 
were enrolled and received three courses of MATRix (rituximab 375 mg/m², intravenous infusion, day 0; methotrexate 
3·5 g/m², the first 0·5 g/m² in 15 min followed by 3 g/m² in a 3 h intravenous infusion, day 1; cytarabine 2 g/m² every 
12 h, in 1 h intravenous infusions, days 2 and 3; thiotepa 30 mg/m², 30 min intravenous infusion, day 4) followed by 
three courses of RICE (rituximab 375 mg/m², day 1; etoposide 100 mg/m² per day in 500–1000 mL over a 60 min 
intravenous infusion, days 1, 2, and 3; ifosfamide 5 g/m² in 1000 mL in a 24 h intravenous infusion with mesna support, 
day 2; carboplatin area under the curve of 5 in 500 mL in a 1 h intravenous infusion, day 2) and carmustine–thiotepa and 
autologous HSCT (carmustine 400 mg/m² in 500 mL glucose 5% solution in a 1–2 h infusion, day –6; thiotepa 5 mg/kg 
in saline solution in a 2 h infusion every 12 h, days –5 and –4). The primary endpoint was progression-free survival at 
1 year. Overall and complete response rates before autologous HSCT, duration of response, overall survival, and safety 
were the secondary endpoints. Analyses were in the modified intention-to-treat population. This study is registered with 
ClinicalTrials.gov, NCT02329080. The trial ended after accrual completion; the database lock was Dec 31, 2019.
Findings Between March 30, 2015, and Aug 3, 2018, 79 patients were enrolled. 75 patients were assessable. 319 (71%) 
of the 450 planned courses were delivered. At 1 year from enrolment the primary endpoint was met, 42 patients were 
progression free (progression-free survival 58%; 95% CI 55–61). 49 patients (65%; 95% CI 54–76) had an objective 
response after MATRix–RICE, 29 (39%) of whom had a complete response. 37 patients who responded had autologous 
HSCT. At the end of the programme, 46 patients (61%; 95% CI 51–71) had an objective response, with a median 
duration of objective response of 26 months (IQR 16–37). At a median follow-up of 29 months (IQR 20–40), 35 patients 
were progression-free and 33 were alive, with a 2-year overall survival of 46% (95% CI 39–53). Grade 3–4 toxicity was 
most commonly haematological: neutropenia in 46 (61%) of 75 patients, thrombocytopenia in 45 (60%), and anaemia 
in 26 (35%). 79 serious adverse events were recorded in 42 (56%) patients; four (5%) of those 79 were lethal due to 
sepsis caused by Gram-negative bacteria (treatment-related mortality 5%; 95% CI 0·07–9·93).
Interpretation MATRix–RICE plus autologous HSCT was active in this population of patients with very poor 
prognosis, and had an acceptable toxicity profile.
Funding Stand Up To Cancer Campaign for Cancer Research UK, the Swiss Cancer Research foundation, and the 
Swiss Cancer League.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Secondary CNS dissemination is a rare but potentially 
lethal event in patients with diffuse large B-cell 
lymphoma. CNS dissemination might present de novo, 
synchronously with systemic disease, or as early CNS 
relapse (isolated or with concomitant systemic disease).1–4 
Secondary CNS lymphoma involves the brain paren-
chyma in 40–50% of patients, leptomeninges in 30–40%, 
Articles
www.thelancet.com/haematology   Vol 8   February 2021 e111
(C Patti MD); AO Parma, Parma, 
Italy (F Re MD); Southampton 
Clinical Trials Unit 
(K Cozens MS) and Cancer 
Research UK Centre 
(A Davies PhD), University of 
Southampton, Southampton, 
UK; International Extranodal 
Lymphoma Study Group 
Coordinating Center, Institute 
of Oncology Research, 
Università della Svizzera 
Italiana, Bellinzona, 
Switzerland (E Gastaldi MS, 
E Zucca MD); Casa Sollievo della 
Sofferenza Hospital, IRCCS, 
San Giovanni Rotondo, Italy 
(N Cascavilla MD); Department 
of Clinical Haematology, 
Nottingham University 
Hospitals NHS Trust, 
Nottingham, UK (C P Fox MD); 
San Bortolo Hospital, Vicenza, 
Italy (M Frezzato MD); 
Department of Haematology, 
Newcastle Upon Tyne Hospitals 
NHS Foundation Trust, 
Newcastle, UK (W Osborne MD); 
Università Degli Studi di 
Perugia—AO Santa Maria, 
Terni, Italy(A M Liberati MD); 
Department of Medical 
Oncology, Inselspital, Bern 
University Hospital, Bern, 
Switzerland (U Novak MD, 
E Zucca); Azienda Ospedaliera di 
Padova, Padua, Italy 
(R Zambello MD); Medical 
Oncology Clinic, Oncology 
Institute of Southern 
Switzerland, Ente Ospedaliero 
Cantonale, Bellinzona, 
Switzerland (E Zucca); Swiss 
Group for Clinical Cancer 
Research, Bern, Switzerland 
(U Novak, E Zucca); Faculty of 
Biomedical Sciences, Università 
della Svizzera Italiana, Lugano, 
Switzerland (E Zucca) 
Correspondence to: 
Dr Andrés J M Ferreri, Lymphoma 
Unit, Department of Onco-
Hematology, IRCCS San Raffaele 
Scientific Institute, 20132 Milan, 
Italy 
ferreri.andres@hsr.it
and both in 10–15%, but the prevalence and timing of 
these events vary due to the diversity of CNS prophylaxis 
strategies.1,5 Neurological symptoms are the first 
indication of CNS disease in many patients, and clinical 
presentation is influenced by the site of the CNS lesions.6 
Secondary CNS lymphoma is frequently associated with 
systemic lymphoma pro gression, concomitantly or 
shortly afterwards; thus, its treatment should be effective 
against both the systemic and the CNS components of 
the disease. Rationally designed treatment protocols 
should use drugs that can be delivered in a dose-
intensive and time-intensive schedule and are effective 
at penetrating the blood–brain barrier, such as 
methotrexate and cytarabine administered at high doses. 
On the basis of retrospective studies,7,8 it is believed that 
potential cure is only achievable if patients have 
autologous haema topoietic stem-cell transplantation 
(HSCT) consolidation after remission of CNS disease. 
Accordingly, conditioning regimens currently used in 
primary CNS lymphoma, which include drugs with 
excellent CNS penetration, such as carmustine, 
busulfan, and thiotepa,9 have been adopted in patients 
with secondary CNS lymphoma.
The highest level of evidence in the treatment of 
secondary CNS lymphoma is from three single-arm 
phase 2 trials on 30–38 patients each.10–12 These trials are 
non-comparable because they used different eligibility 
criteria with variation in upper limits of age, performance 
status, included lymphoma subtypes, previous treatment, 
and response status in the selection of patients for 
autologous HSCT. Additionally, data on some secondary 
CNS lymphoma subgroups, such as patients with CNS 
involvement at presentation and patients with disease 
refractory to the first-line treatment, are scarce because 
these patients were considered in only one of the 
published prospective studies and accounted for less than 
a fifth of the patients enrolled.11
We therefore designed the MARIETTA trial, which 
aimed to assess an intensive, CNS-directed chemo-
immuno therapy consolidated by autologous HSCT in 
patients with secondary CNS lymphoma. Here, we report 
safety and activity results of this trial.
Research in context
Evidence before this study
We searched PubMed between Jan 1, 1990, and Dec 31, 2019, 
for prospective trials investigating the treatment of patients 
with secondary CNS lymphoma. We used the search terms 
“central nervous system”, “CNS”, “lymphoma”, “secondary CNS 
lymphoma”, “SCNSL”, AND “diffuse large B-cell lymphoma”, and 
restricted the results to articles published in English. 
Publications in non-English languages with abstracts in English 
were also considered. Abstract-only data from international 
meetings during the past 3 years (up to Dec 31, 2019) were 
considered. There is little evidence in this field; secondary CNS 
lymphoma is a rare lymphoma and randomised trials are not 
feasible, hence the paucity of data to inform practice. Existing 
literature comprises only three single-arm phase 2 trials 
including at most 38 patients. These are non-comparable trials 
as they have used different eligibility criteria with variation in 
the upper limits of age and performance status as well as in 
considered lymphoma entities, previous treatment, and 
response status in the selection of candidates for autologous 
haematopoietic stem-cell transplantation (HSCT). In addition, 
data on some subgroups, such as patients with CNS 
involvement at initial diagnosis and patients with disease 
refractory to the first-line treatment, are scarce because these 
patients were considered in only one of the published 
prospective studies and accounted for less than a fifth of the 
patients enrolled. The reviewed literature does not allow the 
identification of a standard treatment for patients with 
secondary CNS lymphoma.
Added value of this study
To our knowledge, the MARIETTA study is the largest 
prospective trial focused on patients with secondary CNS 
lymphoma; it was done in 24 centres in four countries, 
representing the most geographically extensive trial to date, 
which supports the generalisability of the results. This trial 
showed that the sequential combination of MATRix (rituximab, 
methotrexate, cytarabine, and thiotepa) and RICE (rituximab, 
ifosfamide, carboplatin, and etoposide) followed by autologous 
HSCT was active in this population of patients with a very poor 
prognosis. Patients aged up to 70 years and with an Eastern 
Cooperative Oncology Group Performance Status of 3 or less 
were included, representing a real-world cohort of patients. 
The MARIETTA programme is active in every subgroup of 
secondary CNS lymphoma, with 1-year progression-free 
survival of 58% (95% CI 55–61) and encouraging 2-year 
progression-free survival of 71% (63–79) in patients with CNS 
disease at initial lymphoma diagnosis. Moreover, the 
MARIETTA programme included two standardised regimens 
(ie, MATRIX and RICE) used in routine practice in several 
countries, and showed a good safety profile.
Implications of all the available evidence
Combined with existing evidence, the results of the 
MARIETTA trial show that a growing proportion of patients 
with secondary CNS lymphoma can have durable remissions 
with intensified chemoimmunotherapy. Patients with CNS 
disease at initial lymphoma diagnosis and patients who had 
CNS dissemination during or after upfront R-CHOP therapy 
have different outcomes, suggesting that these two 
populations of patients with secondary CNS lymphoma might 
benefit from different treatments. Patients with CNS 
involvement at initial diagnosis seemed to benefit from 
treatment with debulking R-CHOP followed by MATRix–RICE 
and autologous HSCT. Further efforts are required to improve 
remission rates before autologous HSCT, especially in patients 
with CNS involvement at first relapse.
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Methods
Study design and participants
The MARIETTA trial is an international, single-arm, 
phase 2 trial done in 24 hospitals in four countries (Italy, 
the UK, the Netherlands, and Switzerland; appendix p 2). 
The trial assessed the safety and activity of a sequential 
combination of MATRix (methotrexate, cytarabine, 
thiotepa, and rituximab)13 followed by RICE (rituximab, 
ifosfamide, carboplatin, and etoposide) and carmustine–
thiotepa conditioned autologous HSCT in patients with 
diffuse large B-cell lymphoma and secondary CNS 
involvement at diagnosis or relapse. These treatment 
combinations were selected following the positive results 
in primary CNS lymphoma14–16 and relapsed or refractory 
diffuse large B-cell lymphoma17 (rationale shown in 
appendix p 4).
The main inclusion criteria were: histologically proven 
diagnosis of diffuse large B-cell lymphoma; CNS involve-
ment (brain, meninges, cranial nerves, eyes, spinal cord, 
or a combination of these) at presentation (concomitant 
to systemic disease) or at relapse (isolated or concomitant 
to systemic lymphoma); age 18–70 years; Eastern 
Cooperative Oncology Group Performance Status 
(ECOG-PS) of 3 or less; and no previous treatment with 
high-dose methotrexate. Both previously untreated 
patients with CNS involvement at initial diagnosis and 
patients with CNS relapse during or after a treatment for 
systemic lymphoma were included. Any previous 
treatment for systemic lymphoma except for high-dose 
methotrexate or autologous or allogeneic HSCT was 
admitted. The upper age limit reflected the eligibility of 
patients to receive autologous HSCT in the participating 
centres. Diagnosis of CNS involvement by either brain 
biopsy, cerebrospinal fluid cytology exam ination, or 
neuroimaging was permitted. Patients with high-grade 
transformation from indolent lymphoma and patients 
with double-hit or triple-hit lymphoma were eligible. 
Patients with a previous organ trans plantation or other 
forms of immuno suppression, HIV infection, or primary 
CNS lymphoma were excluded. Staging and pretreatment 
tests (appendix p 5) were done within 14 days of the start 
of treatment. A full list of inclusion and exclusion criteria 
is in the appendix (p 3). Sociocultural information and 
data on ethnicity were not collected. Written informed 
consent was obtained from each patient. This trial 
conformed to the Declaration of Helsinki and was 
approved by the institutional review boards of the 
participating institutions. The protocol is included in the 
appendix (p 23).
Procedures
After enrolment (appendix p 13), patients received 
three courses of MATRix13 followed by three courses of 
RICE, each delivered every 3 weeks. Patients enrolled at 
initial lymphoma diagnosis (chemotherapy-naive 
patients) with extensive and life-threatening extra-CNS 
disease received one or two courses of R-CHOP 
(rituximab 375 mg/m² as an intravenous infusion on 
day 1; cyclophosphamide 750 mg/m² as an intravenous 
bolus on day 1; doxorubicin 50 mg/m² as an intravenous 
bolus on day 1; vincristine 1·4 mg/m² [maximum 2 mg] 
as an intravenous bolus on day 1; prednisone 75 mg per 
day orally on days 1–5). The MATRix regimen was 
rituximab 375 mg/m² as an intravenous infusion on 
day 0; methotrexate 3·5 g/m², the first 0·5 g/m² in 
15 min followed by 3 g/m² as a 3 h intravenous infusion 
on day 1; cytarabine 2 g/m² every 12 h, in 1 h intravenous 
infusions on days 2 and 3; and thiotepa 30 mg/m² in a 
30 min intravenous infusion on day 4.13 The RICE 
regimen was rituximab 375 mg/m² on day 1; etoposide 
100 mg/m² per day in 500–1000 mL over a 1 h 
intravenous infusion on days 1, 2, and 3; ifosfamide 
5 g/m² in 1000 mL in a 24 h intravenous infusion with 
mesna support on day 2; and carboplatin area under the 
curve of 5 in 500 mL in a 1 h intravenous infusion on 
day 2. Intrathecal chemotherapy was indicated in every 
enrolled patient regardless of cerebrospinal fluid 
cytology status because conventional cytology exam-
ination is associated with frequent false negative results, 
particularly when flow cytometry is not routinely used.6 
Accordingly, a dose of intrathecal liposomal cytarabine 
50 mg or conventional triple-drug chemotherapy 
(intrathecal methotrexate 12 mg, cytarabine 50 mg, and 
hydrocortisone 50 mg) was delivered on day 5 of every 
course of MATRix and on day 4 of every course of RICE. 
Per protocol, antimicrobial prophylaxis followed insti-
tutional guidelines; however, oral antiviral, antifungal, 
and antipneumocystic prophylaxis plus conventional 
doses of recombinant granulocyte-colony stimulating 
factor (G-CSF; exact molecule chosen by investigators) 
from day 6 to 12 of every chemotherapy course was 
suggested.
The protocol mandated that patients with stable or 
progressive disease during MATRix treatment would 
immediately switch to the RICE regimen (appendix p 13), 
with patients with subsequent CNS progression events 
receiving whole-brain radiotherapy before proceeding 
with autologous HSCT consolidation. The whole-brain 
radiotherapy dose was 36 Gy plus a tumour-bed boost of 
10 Gy. The whole brain was irradiated by two opposite 
lateral fields, including the first two cervical vertebrae 
and the posterior two-thirds of the eyes, which had to 
be shielded after 30 Gy (photons of 4–10 MeV, 
180–200 cGy per day, five weekly fractions). Autologous 
peripheral blood stem cells were collected after the 
second course of MATRix and were processed according 
to con ventional guidelines. Patients with a complete or 
partial response after MATRix–RICE and with adequate 
autologous peripheral blood stem cell harvest received 
autologous HSCT (appendix p 13). Myeloablative 
chemotherapy consisted of carmustine 400 mg/m² in 
500 mL glucose 5% solution in a 1–2 h infusion on 
day –6; thiotepa 5 mg/kg in saline solution in 2 h 
infusions every 12 h on day –5 and –4, supported by 
See Online for appendix
Articles
www.thelancet.com/haematology   Vol 8   February 2021 e113
autologous HSCT. In case of carmustine unavailability, 
the recommended conditioning regimen was: thiotepa 
5 mg/kg in 100 mL of saline solution by 2 h infusion on 
day –6 and –5; busulfan 3·2 mg/kg (admin istered in 
four doses per day corresponding to 0·8 mg/kg each 
dose) by 2 h infusion or 3·2 mg/kg as a once daily 
infusion given over 3 h, on days –4, –3, and –2. Patients 
with residual disease in the brain parenchyma after 
autologous HSCT received whole-brain radiotherapy; 
patients with residual disease in the cerebrospinal fluid 
after autologous HSCT received additional, intensified 
intrathecal chemotherapy (methotrexate 12 mg plus 
cytarabine 50 mg plus hydrocortisone 50 mg on days 1 
and 8 each month for 3 months, or thiotepa 10 mg plus 
rituximab 25 mg on days 4 and 11 each month for 
3 months, or both).
Toxicities were graded according to the National Cancer 
Institute–National Cancer Institute of Canada Common 
Toxicity Criteria (NCI–NCIC CTC) version 4.0.18 The 
worst toxicity per organ, per course was considered. 
Adverse events were assessed during the visit before 
each course or during hospitalisation, when required. 
Severe adverse events are defined in the protocol 
(appendix p 23). Tumour response was assessed by 
gadolinium-enhanced brain MRI, ¹⁸F-fluorodeoxyglucose 
PET, contrast-enhanced total-body CT scan, and other 
examinations that were positive at baseline, after the 
second course of MATRix, the first course of RICE, the 
third course of RICE, and after autologous HSCT. 
Response definition of CNS disease followed the 
International Primary CNS Lymphoma Collaborative 
Group response criteria19 and extra-CNS disease followed 
the Revised Response Criteria for Malignant Lymphoma.20 
The maximum response recorded from treatment start 
was considered for analyses and therapeutic decisions 
were based on local investigator assessment. After the 
end of treatment, the disease was assessed every 
3 months for the first 2 years, and every 6 months during 
the third, fourth, and fifth years.
Outcomes
The primary endpoint was progression-free survival at 
1 year. The secondary endpoints were overall and 
complete response rate before autologous HSCT, 
duration of response, overall survival, and safety. 
Progression-free survival and overall survival were 
estimated according to the Revised Response Criteria for 
Malignant Lymphoma.20 The best response achieved 
during experimental treatment was considered for 
analyses, and duration of response was estimated for 
patients who had a response to MATRix–RICE as the 
time between the date of best response and the date of 
relapse, progressive disease, death from any cause, or last 
follow-up visit. Stable disease during MATRix that 
required crossing to RICE, or stable disease during RICE 
that required crossing to whole-brain radiotherapy, was 
not considered an event in survival analyses. The effects 
of treatment on patient-reported outcomes (acceptability 
and quality of life) were not assessed.
Post-hoc exploratory analyses were to define differences 
in progression-free survival between patients with CNS 
localisation at initial diagnosis and patients with CNS 
involvement at relapse, difference in progression-free 
survival between patients with histo logically confirmed 
CNS disease and patients assessed with neuroimaging 
alone, the role of debulking R-CHOP and intrathecal 
chemotherapy, and the prognostic value of age, sex, 
performance status, lactate dehydrogenase serum 
concentration, sites of disease, response to the first two 
MATRix courses, a history of indolent lymphoma, and 
cell of origin.
Statistical analysis
The Fleming design was used. The maximum 
progression-free survival at 1 year considered of low 
interest was 50% (null hypothesis)10 and the minimum 
progression-free survival at 1 year considered of interest 
was 65% (alternative hypothesis). In other words, an 
experimental treatment associated with a 1-year 
progression-free survival of less than 50% would not be a 
suitable strategy for routine use and further research. To 
detect such a difference 69 patients were required (one-
sided test, type I error 5%, and power 80%); with a 
10% dropout, 76 patients were needed. If at least 
41 patients were progression-free survivors at 1 year, the 
strategy would be considered effective. All registered 
patients were considered for primary and safety analyses 
except for patients who post hoc objectively did not meet 
the eligibility criteria, including incorrect histopatho-
logical diagnosis, concomitant cancer, or disease only at 
flow cytometry examination of the cerebrospinal fluid 
(modified intention-to-treat analysis). Patients were 
excluded from analyses in the case of consensus 
withdrawal.
Progression-free survival and overall survival curves 
were generated using the Kaplan-Meier method, 
expressed with standard error, and compared through 
the log-rank test. 95% CI was provided for any data 
derived from Kaplan-Meier analyses. Time at risk started 
at the day of trial enrolment for all the analyses except 
the analysis of response to MATRix, for which the time 
at risk started at the date of response assessment after 
the first two MATRix courses.
Independent association between studied variables and 
survival were tested using the Cox proportional hazard 
model. Variables that achieved statistical significance 
(p<0·05) in univariate analyses were considered for the 
multivariable analysis. Variables addressed by unplanned 
exploratory analyses were not included in the multi-
variable analysis. All the probability values were two-
sided. All analyses were done using the Statistica 10.0 
statistical package for Windows (Statsoft, 2011, Tulsa, 
OK, USA). This study was registered with ClinicalTrials.
gov, NCT02329080.
For the Statistica package see 
https://www.statistica.com/en/
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Figure 1: Trial profile
HSCT=high-dose chemotherapy supported by autologous haematopoietic stem-cell transplantation. MATRix=rituximab, methotrexate, cytarabine, and thiotepa. 
RICE=rituximab, ifosfamide, carboplatin, and etoposide. WBRT=whole-brain radiotherapy. Adjuvant radiotherapy is radiotherapy used in patients in complete 
remission after autologous HSCT. Complementary radiotherapy is irradiation of residual lesions in patients in partial response after autologous HSCT. *Four patients 
were excluded because of unrelated laboratory abnormalities (n=2), disease only at flow cytometry examination of the cerebrospinal fluid (n=1), and death at the 
same time as registration (n=1). †Per protocol, MATRix was preceded by debulking R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) 
in nine (28%) of the 32 patients enrolled at original lymphoma diagnosis. ‡Protocol deviations. §Patients still had progressive disease after the WBRT.
79 patients enrolled
75 received first MATRix course†
66 received second MATRix course
48 received third MATRix course 
55 received first RICE course 
43 received second RICE course
37 autologous HSCT
2 partial response
1 complementary radiotherapy (WBRT)





1 right inguinal region
32 received third RICE course
19 complete response
10 partial response (1 WBRT with partial response)
4 excluded*
1 progressive disease and proceeded to RICE 
(CNS plus systemic)
1 complete response and proceeded to autologous HSCT‡
8 withdrew from study
3 toxic deaths
4 progressive disease (3 CNS; 1 CNS plus systemic)
1 lost to follow-up (partial response)
9 withdrew from study
1 toxic death
3 progressive disease (1 CNS; 2 systemic)
1 toxicity (complete response)
1 poor mobiliser (complete response)
1 neurological worsening (partial response)
2 physician's decision (partial response)
9 proceeded to RICE
    2 complete response‡
    3 partial response‡
    1 stable disease
    3 progressive disease (1 CNS; 2 CNS plus systemic)
2 withdrew from study
2 progressive disease (CNS plus systemic)
7 withdrew from study
1 frailty (partial response)
6 progressive disease (1 CNS; 5 CNS plus systemic) 
1 WBRT§
5 proceeded to autologous HSCT
4 complete response‡
1 partial response‡ (WBRT with complete response)
2 partial response and proceeded to autologous HSCT‡ 
(1 WBRT with partial response)
9 withdrew from study




2 poor mobiliser (complete response) 
1 WBRT 
3 withdrew from study
2 progressive disease (CNS)
2 WBRT§ 




2 stable disease‡ 
1 progressive disease‡ (CNS plus systemic)
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Role of the funding source
Neither the sponsor nor the grant provider for the study 
had any role in study design, data collection, data 
analysis, data interpretation, or writing of the report. All 
the authors had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between March 30, 2015, and Aug 3, 2018, 79 patients 
were enrolled. Every patient who was eligible according 
to the per-protocol selection criteria and diagnosed at 
participating centres was enrolled. The trial was ended 
after accrual completion; the database lock was 
Dec 31, 2019. Four patients were excluded after enrolment 
before the start of study treatment because of unrelated 
laboratory abnormalities (two patients), disease only at 
flow cytometry examination of the cerebrospinal fluid 
(one), and death at the same time as registration (one). 
75 patients with a median age of 58 years (IQR 50–66) 
were assessable and received the first MATRix course 
(figure 1), 38 (51%) of whom were male and 37 (49%) of 
whom were female (table 1; appendix p 6).
R-CHOP was the first-line treatment in most of the 
43 patients registered at relapse, with a median time to 
CNS involvement of 5 months (IQR 2–8). Of these 
43 patients, 39 (91%) had CNS relapse during the first year 
of follow-up and 20 (47%) had a systemic lymphoma 
refractory to the previous line of treatment; refractoriness 
was defined as progressive disease occurring during 
treatment or at re-staging after the last course of 
chemotherapy. 13 (17%) of 75 patients had a previous 
indolent lymphoma (ten [13%] had follicular lymphoma, 
one [1%] had lympho plasmacytic lymphoma, one [1%] had 
marginal zone lymphoma, and one [1%] had chronic 
lymphocytic leukaemia); transformation to diffuse large 
B-cell lymphoma in the CNS was confirmed by brain 
biopsy in these 13 patients. Characteristics of patients with 
transformed lymphoma and de-novo diffuse large B-cell 
lymphoma are shown in the appendix (p 7). The cell of 
origin was defined according to Hans algorithm; complete 
data were available for 64 (85%) patients and at least 
one immunostaining was absent in the other 11 (15%) 
Patients (n=79)
Eligible patients (study population) 75





CNS involvement at presentation 32 (43%)
Isolated CNS relapse 15 (20%)
Concomitant CNS–systemic localisation 28 (37%)
HBV or HCV seropositivity 2 (3%)
Symptoms at enrolment
B symptoms* 6 (8%)
Motor impairment 37 (49%)
Sensorial impairment 25 (33%)
Language impairment 7 (9%)
Cognitive impairment 15 (20%)
Sensorial impairment 12 (16%)
CNS sites of disease
Brain parenchyma 34 (45%)
Cerebrospinal fluid or meninges 8 (11%)
Spinal cord 2 (3%)
Eyes 2 (3%)
Brain and cerebrospinal fluid or meninges 13 (17%)
Brain and eyes 10 (13%)
Brain, cerebrospinal fluid, and eyes 6 (8%)
Extra-CNS sites of disease at enrolment
None 15 (20%)
Nodal disease (only lymphadenopathies) 18 (24%)
Extranodal disease (other than CNS) 18 (24%)
Nodal and extranodal disease 24 (32%)
Extranodal disease at initial lymphoma diagnosis† 59 (79%)
(Table 1 continues in next column)
Patients (n=79)
(Continued from previous column)
IPI
Age >60 years 32 (43%)
ECOG-PS >1‡ 28 (37%)
Number of extranodal organs 
involved >1 (other than CNS)
23 (31%)
High LDH serum concentration 37 (49%)
Advanced stage 60 (80%)
Low IPI risk 14 (19%)
Low–intermediate IPI risk 18 (24%)
High–intermediate IPI risk 26 (35%)
High IPI risk 17 (23%)
Previous treatment 43 (57%)
R-CHOP 40 (93%)




Previous CNS prophylaxis (only intrathecal 
chemotherapy)
7 (16%)
Refractory to previous treatment (n=43) 20 (47%)
Data are median (IQR; range) or n (%). DA-R-EPOCH=dose-adjusted rituximab, 
etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin. 
ECOG-PS=Eastern Cooperative Oncology Group Performance Status. 
HBV=hepatitis B virus. HCV=hepatitis C virus. IPI=International Prognostic Index. 
LDH=lactate dehydrogenase. R-CHOP=rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone. R-VACOP=rituximab, etoposide, doxorubicin, 
cyclophosphamide, vincristine, and prednisone. *B symptoms are systemic 
symptoms—ie, fever of unknown origin, night sweats,and weight loss. †Details on 
involved extranodal organs are provided in the appendix (p 6). ‡Median ECOG-PS 
was 1, with score 0 in 15 (20%) patients, 1 in 32 (43%) patients, 2 in 20 
(27%) patients, and 3 in eight (11%) patients.
Table 1: Baseline characteristics
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patients with unclassifiable lymphomas. 38 (59%) of the 
64 assessed lymphomas were non-germinal-centre-like 
subtype.
At 1 year from enrolment, 42 patients were progression 
free; with a 1-year progression-free survival of 58% 
(95% CI 55–61) for the total assessable population 
and 100% (100–100) for the patients who received a 
transplant (figure 2A–B). At a median follow-up of 
29 months (IQR 20–40), 35 (47%) of the 75 assessable 
patients were progression free; three of them died without 
evidence of lymphoma relapse at 13 months (sudden 
death), 16 months (progressive neurological decline), and 
31 months (suspected pulmonary thrombo embolism). 
25 (33%) of 75 patients had progressive disease during 
chemotherapy at every step of experimental treatment, 
11 (24%) of 46 responders had tumour relapse. Most 
organs involved at relapse or progression were primary 
sites of disease (appendix p 9). In exploratory analyses, 
2-year progression-free survival was 46% (95% CI 39–53) 
for the total assessable population and 83% (82–84) for 
transplanted patients (figure 2A–B). Furthermore, the 
30 patients with histologically confirmed CNS disease 
and the 45 patients assessed with neuroimaging alone 
had similar progression-free survival at 2 years 
(43% [95% CI 30–55] vs 47% [39–55]; p=0·67).
Progressive and relapsing disease were very aggressive; 
only seven (19%) of 36 patients received salvage therapy, 
with no responses, and with a median survival after relapse 
or progression from MARIETTA treatment of 1 month 
(IQR 1–3). Therefore, overall survival was similar to 
progression-free survival in each subset of patients 
analysed (figure 2; appendix p 14). 33 patients were alive at 
last follow-up, with a 2-year overall survival of 46% 
(95% CI 39–53) for the total assessable population and 83% 
(82–84) for transplanted patients (appendix p 14).
The 75 assessable patients received the first course of 
MATRix; per protocol, MATRix was preceded by 
debulking R-CHOP in nine (28%) of the 32 patients 
enrolled at original lymphoma diagnosis. Post-hoc 
analysis showed that 55 (73%; 95% CI 63–83) patients 
had an objective response after two courses of MATRix 
(table 2). 19 (95%) of the 20 patients who had a complete 
response after two courses of MATRix maintained the 
remission after crossing to RICE; 36 patients achieved 
partial tumour response as the best response during the 
first two courses of MATRix (one after the first course 
and 35 after the second one): 28 of them received the 
third course of MATRix and crossed to RICE, three 
crossed directly to RICE (protocol violation), one received 
the third course of MATRix and had progressive disease, 
and four did not receive other treatment. 24 (77%) of the 
31 patients who had RICE after a partial response after 
two courses of MATRix maintained or improved response 
after RICE. Three (4%) of 75 patients had stable disease 
after two courses of MATRix: one received the third 
course of MATRix and had disease progression, one 
received the third course of MATRix and crossed to 
RICE, and one crossed directly to RICE; the last two 
patients had a major response and received autologous 
HSCT. 12 (16%) of 75 patients had progressive disease 
during the first two courses of MATRix (figure 1); per 
protocol, five (7%) patients crossed to RICE (preceded by 
a third course of MATRix in one of them), had further 
progressive disease, and died early; the other seven (11%) 
patients did not receive other treatment because they had 
aggressive progressive disease, with fast impairment of 
neurological and general conditions that impeded any 
Figure 2: Kaplan-Meier curves of progression-free survival
(A) Progression-free survival of the assessable population. (B) Progression-free 
survival of the 37 transplanted patients. (C) Progression-free survival of the 



























































Patients enrolled at initial diagnosis











































































































Complete response 20 (27%) 26 (35%) 26 (43%) 11 (34%) 4 (27%) 5 (18%)
Partial response 36 (48%) 31 (41%) 19 (32%) 17 (53%) 6 (40%) 13 (46%)
Objective response 56 (75%) 57 (76%) 45 (75%) 28 (88%) 10 (67%) 18 (64%)
Stable disease 3 (4%) 6 (8%) 3 (5%) 1 (3%) 1 (7%) 1 (4%)
Progressive disease 12 (16%) 8 (11%) 10 (17%) 3 (9%) 2 (13%) 7 (25%)
After MATRix–RICE
Complete response 29 (39%) 37 (49%) 33 (55%) 17 (53%) 6 (40%) 6 (21%)
Partial response 20 (27%) 14 (19%) 12 (20%) 10 (31%) 3 (20%) 7 (25%)
Objective response 49 (65%) 51 (68%) 45 (75%) 27 (84%) 9 (60%) 13 (46%)
Stable disease 0 0 0 0 0 0
Progressive disease 22 (29%) 20 (27%) 13 (22%) 5 (16%) 4 (27%) 13 (46%)
Whole treatment
Complete response 41 (55%) 44 (59%) 40 (67%) 24 (75%) 7 (47%) 9 (32%)
Partial response 5 (7%) 2 (3%) 4 (7%) 2 (6%) 0 3 (11%)
Objective response 46 (61%) 46 (61%) 44 (73%) 26 (81%) 7 (47%) 12 (43%)
Stable disease 0 0 0 0 0 0
Progressive disease 25 (33%) 25 (33%) 14 (23%) 6 (19%) 6 (40%) 14 (50%)
Data are n (%). Whole series column shows all responses in all patients, CNS disease column shows responses related 
only to CNS disease (all patients); and systemic disease column shows responses only related to extra-CNS disease in 
patients who had extra-CNS disease. MATRix=methotrexate, cytarabine, thiotepa, and rituximab. RICE=rituximab, 
ifosfamide, carboplatin, and etoposide. *Four patients died of toxicity during MATRix; two of them had concomitant 
systemic disease.
Table 2: Responses of CNS and systemic disease at different timepoints of protocol treatment
further treatment. There were 19 protocol deviations 
(figure 1).
49 patients (65%; 95% CI 54–76) had an objective 
response after MATRix–RICE induction: response was 
complete in 29 (39%; 28–50) patients and partial 
in 20  (27% [95% CI 17–37]; eight [40%] patients had 
residual disease in the CNS, six [30%] had residual 
disease in extra-CNS organs, and six [30%] patients had 
residual disease in both).
48 (64%) patients were referred for leukapheresis 
for autologous peripheral blood stem-cell collection 
(appendix p 8). This procedure was successful (>2 × 10⁶ 
CD34+ cells per kg) in 42 (88%) of the 48 patients, with a 
median of 6·75 × 10⁶ CD34+ cells per kg (IQR 5–8). 
Autologous peripheral blood stem cells collected after a 
previous line of treatment and stem cells collected by 
marrow harvest were used in one patient each.
12 (24%) of the 49 responders were not eligible for 
autologous HSCT (figure 1); four (33%) of the 12 remained 
relapse-free at 18–28 months of follow-up. 37 (76%) of the 
49 responders (25 complete responses; 12 partial 
responses) received autologous HSCT. In the 12 patients 
with partial responses, residual disease was in the CNS in 
four (33%), in systemic organs in three (25%), and in 
both in five (42%). Ten (83%) of the 12 patients with 
partial responses had a complete response after 
autologous HSCT; three of them received non-protocol 
planned, post-transplant adjuvant radio therapy based on 
the decision of the physician, and the two patients with 
residual disease after trans plantation received radio-
therapy (figure 1). Including the two patients who received 
whole-brain radiotherapy after autologous HSCT, 13 (17%) 
patients received whole-brain radiotherapy as part of 
experimental treatment: nine received radiotherapy due 
to residual (five patients) or progressive (four patients) 
disease in the brain after or during MATRix–RICE; 
two patients in complete response after MATRix–RICE 
received whole-brain radio therapy because they were 
poor mobilisers. Seven (78%) of the nine patients who 
received whole-brain radio therapy to control responsive 
disease had a complete or partial response and only one 
of them had relapsing disease in the brain. None of the 
four patients who received whole-brain radiotherapy to 
control progressive disease in the brain responded; all of 
them died within 9 months of trial enrolment.
46 patients (61%; 95% CI 51–71) had objective evidence 
of response at initiation of follow-up, with complete 
response in 41 patients (55%; 44–66). The median duration 
of response was 26 months (IQR 16–37).
42 (56%) patients died; causes were lymphoma (n=35), 
toxicity (n=4), progressive neurological decline (n=1), and 
pulmonary thromboembolism (n=1); cause of death is 
unknown in one patient (sudden death).
No cases of unexpected toxicity were recorded after 
debulking R-CHOP. 319 (71%) of the 450 planned 
MATRix–RICE courses were delivered (appendix p 10); 
dose reductions were indicated in 32 (10%) courses in 
24 (32%) patients. Interruptions due to toxicity occurred 
only during MATRix: interruption was permanent in four 
patients and transient in five patients (appendix p 10). 
64 (85%) patients received intrathecal chemotherapy. 
Grade 3–4 toxicity was almost exclusively haemato-
lo gical (table 3): neutropenia in 46 (61%) patients, 
Grade 1–2 Grade 3 Grade 4 Grade 5
Neutropenia 2 (3%) 5 (7%) 41 (55%) 0
Anaemia 8 (11%) 22 (29%) 4 (5%) 0
Thrombocytopenia 2 (3%) 1 (1%) 44 (59%) 0
Infections 17 (23%) 14 (19%) 8 (11%) 4 (5%)
Hepatotoxicity 8 (11%) 13 (17%) 0 0
Nephrotoxicity 7 (9%) 0 1 (1%) 0
Mucositis 8 (11%) 3 (4%) 1 (1%) 0
Nausea, vomiting, or 
diarrhoea
17 (23%) 3 (4%) 0 0
Central and peripheral 
neurotoxicity
10 (13%) 3 (4%) 0 0
Cardiotoxicity 2 (3%) 1 (1%) 0 0
Vascular events* 2 (3%) 1 (1%) 1 (1%) 0
Grade 1 or 2 adverse events are reported if occurring in at least 10% of patients in 
the treated population (n=75). In patients with multiple concomitant toxicities, 
each side-effect was considered and reported in the table separately. *Deep vein 
thrombosis, pulmonary thromboembolism, or stroke.
Table 3: Adverse events
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thrombocytopenia in 45 (60%), and anaemia in 26 (35%). 
Grade 3 infections occurred in 14 (19%) patients and grade 
4 in eight (11%) patients; grade 3 neutropenic fever 
occurred in ten (13%) patients and grade 4 in one (1%) 
patient (appendix p 10). 79 serious adverse events (all 
grades) were recorded in 42 (56%) patients, mostly febrile 
neutropenia (n=39 episodes) and infections (n=25). 
Serious adverse events also included bleeding (n=4), bowel 
perforation (n=2), acute renal failure (n=2), acute 
neurotoxicity (n=2), pulmonary thrombo embolism (n=1), 
atrial fibrillation (n=1), vomiting plus diarrhoea (n=1), 
ischaemic stroke (n=1), and increased alanine amino-
transferase (n=1). Hospital admission was prolonged in 
72 (91%) of 79 serious adverse events; 75 (95%) serious 
adverse events were followed by recovery, four (5%) were 
lethal due to sepsis caused by Gram-negative bacteria 
(Enterococcous faecalis and Escherichia coli; treatment-
related mortality 5%; 95% CI 0·07–9·93). The lethal 
serious adverse events occurred during MATRix (appendix 
p 10). There were no differences in toxicity between 
treatment-naive and previously treated patients: 32 serious 
adverse events were recorded in 16 (50%) of 32 treatment-
naive patients and 47 serious adverse events were recorded 
in 26 (60%) of 43 previously treated patients (p=0·48); 
MATRix dose reductions were indicated in nine (28%) of 
32 treatment-naive patients and in 15 (35%) of 43 previously 
treated patients (p=0·53). In the 55 patients in whom RICE 
was started, RICE dose reductions were indicated in 
five (19%) of 27 treatment-naive patients and three (11%) of 
28 previously treated patients (p=0·77). MATRix was 
interrupted in three (9%) of 32 treatment-naive patients 
and six (14%) of 43 previously treated patients (p=0·54). 
The most common toxicities after autologous HSCT were 
haema tological, followed by mucositis (appendix p 10).
Some post-hoc exploratory subgroup analyses were 
done. Univariate analyses showed that patients with CNS 
localisation at initial diagnosis had a significantly improved 
progression-free survival compared with patients with 
CNS involvement at relapse, with a 2-year progression free 
survival of 71% (95% CI 69–73) for the 32 patients enrolled 
at initial lymphoma diagnosis and 28% (11–47) for the 
43 patients enrolled at relapse (p=0·0031; figure 2C; 
appendix p 11). Multivariable analysis showed that CNS 
involvement at initial lymphoma diagnosis (vs CNS 
involvement at relapse) and complete response to the first 
two MATRix courses were independently associated with 
improved progression-free survival (appendix pp 11, 
15–16). Notably, the 28 patients enrolled at initial diagnosis 
with lymphoma responsive to MATRix had a 2-year 
progression-free survival of 77% (95% CI 76–78; 
appendix p 17). 
Eight (89%) of the nine patients enrolled at initial 
diagnosis who received debulking R-CHOP before 
MATRix were relapse-free survivors at 26–47 months of 
follow-up (appendix p 18). The use of intrathecal chemo-
therapy was significantly associated with improved 
progression-free survival (appendix p 19); the 11 patients 
who did not receive intrathecal chemo therapy had a 
contraindication to lumbar puncture due to large brain 
lesions; only one of these patients remained relapse-free 
at 42 months of follow-up, with a 2-year progression-free 
survival of 18% (95% CI 0–36) compared with 47% (37–57) 
for the 64 patients who received intrathecal chemotherapy 
(p=0·012). The type of intrathecal chemo therapy used 
(conventional triple drug vs liposomal cytarabine) had no 
effect on progression-free survival (appendix p 19). The 
history of indolent lymphoma and cell of origin were not 
associated with outcome (appendix pp 20–21). Age, sex, 
performance status, and lactate dehydrogenase serum 
level were not independently associated with outcome 
(appendix p 11).
Discussion
To our knowledge, the MARIETTA study is the largest 
prospective trial focused on patients with secondary CNS 
lymphoma; it was done in 24 centres in four countries, 
representing the most geographically extensive trial in 
patients with secondary CNS lymphoma to date, which 
supports the generalisability of results. This trial showed 
that the sequential combination of MATRix and RICE 
followed by autologous HSCT was active in this population 
of patients with a very poor prognosis, meeting the 
predetermined threshold for progression-free survival, 
without major safety concerns. Response to MATRix was 
an independent favourable prognostic factor, whereas 
patients with MATRix-refractory disease had little benefit 
from crossing to RICE and autologous HSCT. Survival of 
patients who had a transplantation was encouraging, with 
significantly improved progression-free survival and 
overall survival in chemotherapy-naive patients treated at 
presentation compared with patients who had CNS 
relapse after a first-line chemoimmunotherapy.
This trial has a few limitations. In particular, the rarity 
of secondary CNS lymphoma makes it difficult to do 
randomised trials and only single-arm phase 2 trials 
seem to be feasible in this patient population. 
Importantly, the MARIETTA trial considered patients 
with CNS involve ment at both initial diagnosis and 
relapse, including patients with high-grade transformed 
diffuse large B-cell lymphoma, and both with isolated 
CNS relapse and concomitant CNS–systemic disease, 
which might have generated an interpretation bias 
related to an apparent study population heterogeneity, 
reducing the strength of the reported associations. 
However, patient heterogeneity is a characteristic of this 
rare lymphoma, and the patients enrolled in this trial 
reflect the situation in routine practice, with the exception 
of patients older than 70 years who were excluded; thus, 
the use of the MARIETTA programme in older patients 
should be considered with caution. Moreover, studies 
clearly reporting the ratio between CNS involvement at 
presentation and at relapse in routine practice do not 
exist, which does not allow us to put the patient 
distribution in the present trial in context. However, the 
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relatively large sample size of the MARIETTA trial 
allowed us to draw reliable conclusions on safety and 
activity in the whole study population and to distinguish 
different outcomes between patients with CNS disease at 
initial lymphoma diagnosis and patients who had CNS 
dissemination during or after upfront R-CHOP therapy, 
suggesting that these two secondary CNS lymphoma 
populations might benefit from different treatments. 
This finding is an important contribution considering 
that only one previous study focused on patients with 
CNS involvement at initial diagnosis of diffuse large 
B-cell lymphoma exists, which included only 16 patients 
with this condition.11 An additional limitation was that no 
centralised review of imaging was done, and response 
and relapse assessment by local investigators of 
the 24 participating institutions was used as supportive 
evidence, which might have generated an interpretation 
bias. However, we can exclude a biased effect on the 
primary endpoint of the trial because progressive or 
relapsing disease is a clear condition to treating 
physicians, usually associated with relevant symptoms 
and general or neurological impairment. The MARIETTA 
programme was feasible, with 71% of MATRix–RICE 
courses delivered, and only four (5%) patients having 
permanent interruptions (appendix p 10) due to lethal 
sepsis. Although these rates seem to be a little better than 
that expected in routine practice, we cannot put these 
figures in context because retrospective studies on 
patients treated in everyday practice were not designed to 
answer this question. Finally, neurotoxicity was an 
uncommon event in patients treated with the MARIETTA 
programme; however, potential late cognitive decline 
cannot be excluded because assessment by neuro-
psychological tests was not included in the trial design.
When putting the MARIETTA trial in context with 
previous trials, we note that the study population includes 
a relatively large proportion of patients with a poor 
prognosis (appendix p 12): 47% of patients had R-CHOP-
refractory lymphoma, 80% of patients had concomitant 
systemic disease, and 56% had extra-CNS extranodal 
disease; all these are well known negative prognosticators, 
which makes it difficult to compare these results with 
previous trials (three multicentre, single-arm, phase 2 
trials done in Germany,10 Italy,11 and the Netherlands12). The 
only study published at the time of design of the 
MARIETTA trial was used to estimate the present sample 
size.10 In that trial, a methotrexate–ifosfamide combination 
followed by cytarabine–thiotepa combination and 
autologous HSCT had been adopted in 30 patients, 
reporting a complete response rate after induction of 23%, 
and a 1-year progression-free survival of 49% for the whole 
population and 58% for transplanted patients. Comparison 
between that study and the MARIETTA trial is limited by 
some relevant differences in selection criteria. In the 
previous trial,10 the upper age limit was 65 years, with an 
upper limit of ECOG-PS of 2; patients with CNS 
involvement at initial lymphoma diagnosis were not 
considered, whereas patients with T-cell lymphomas were 
also enrolled. The SCNSL1 study11 used similar selection 
criteria to those used in the MARIETTA trial. The 
characteristics of the 38 patients enrolled in the SCNSL1 
trial are similar to those recorded for the present study 
population (appendix p 12), with the exception of eligible 
histology (as a few patients with follicular lymphoma or 
mantle cell lymphoma were enrolled in the SCNSL1 trial) 
and, importantly, the proportion of patients with disease 
refractory to the previous line of treatment, which was 
almost three times greater in the MARIETTA trial.
The chemoimmunotherapy combination assessed in 
the MARIETTA trial was active in every subgroup of 
secondary CNS lymphoma, with the best results shown 
in patients with CNS disease at initial lymphoma 
diagnosis (43% of the enrolled participants). The SCNSL1 
trial has shown a 2-year progression-free survival of 
45% in a group of 16 patients with CNS disease at initial 
diagnosis,11 and to our knowledge no other trials have 
focused on this crucial subgroup of patients. In our study, 
we report a 2-year progression-free survival of 71% 
(appendix p 11), an encouraging result considering that 
the 2-year progression-free survival for patients with 
diffuse large B-cell lymphoma without CNS involvement 
treated with R-CHOP is 70–75%.21
The safety profile of the MARIETTA programme could 
be considered to be favourable compared with that 
reported in the SCNSL1 trial, which consisted of an 
intensified strategy associated with grade 3–4 infections or 
febrile neutropenia in 24% of delivered courses (compared 
with 13% in the MARIETTA trial; appendix p 10) and 11% 
treatment-related mortality (compared with 5% in the 
MARIETTA trial). Importantly, intensification  high-dose 
sequential chemoimmuno therapy of the SCNSL1 trial is 
used only in selected centres in Italy, whereas MATRix 
and RICE are two standardised regimens that are used in 
routine practice in several countries. A study from June, 
2020,22 shows that MATRix is used in routine practice in 
many cancer centres with similar activity and tolerability 
to that reported within prospective trials.13
In conclusion, the results of the MARIETTA trial are a 
step forward in the treatment of secondary CNS 
lymphoma. In particular, progression-free survival for 
transplanted patients is encouraging and constitutes a 
good platform to discuss future strategies in this hard-
to-treat patient cohort. Patients with CNS involvement 
at initial diagnosis seem to benefit from treatment with 
debulking R-CHOP followed by MATRix–RICE and 
autologous HSCT. Further efforts are urgently required 
to improve remission before transplantation, especially 
in patients with CNS involvement at first relapse. 
Different therapies for patients with CNS involvement 
at presentation or relapse should be addressed in future 
trials.
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